Merck & Company Inc - Asset Resilience Ratio
Merck & Company Inc (MRK) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Merck & Company Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Merck & Company Inc's Asset Resilience Ratio has changed over time. See MRK net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Merck & Company Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Merck & Company Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $375.00 Million | 0.29% |
| Total Liquid Assets | $375.00 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Merck & Company Inc maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Merck & Company Inc Industry Peers by Asset Resilience Ratio
Compare Merck & Company Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Merck & Company Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Merck & Company Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.64% | $14.56 Billion | $136.87 Billion | -1.05pp |
| 2024-12-31 | 11.69% | $13.69 Billion | $117.11 Billion | +5.04pp |
| 2023-12-31 | 6.65% | $7.09 Billion | $106.67 Billion | -5.44pp |
| 2022-12-31 | 12.09% | $13.19 Billion | $109.16 Billion | +4.43pp |
| 2021-12-31 | 7.66% | $8.10 Billion | $105.69 Billion | -1.14pp |
| 2020-12-31 | 8.80% | $8.06 Billion | $91.59 Billion | -3.58pp |
| 2019-12-31 | 12.38% | $10.45 Billion | $84.40 Billion | +1.66pp |
| 2018-12-31 | 10.73% | $8.86 Billion | $82.64 Billion | +1.06pp |
| 2017-12-31 | 9.67% | $8.50 Billion | $87.87 Billion | -5.37pp |
| 2016-12-31 | 15.04% | $14.34 Billion | $95.38 Billion | +10.21pp |
| 2015-12-31 | 4.82% | $4.90 Billion | $101.68 Billion | -3.61pp |
| 2014-12-31 | 8.43% | $8.28 Billion | $98.17 Billion | +6.67pp |
| 2013-12-31 | 1.77% | $1.86 Billion | $105.64 Billion | -0.77pp |
| 2012-12-31 | 2.53% | $2.69 Billion | $106.13 Billion | +1.16pp |
| 2011-12-31 | 1.37% | $1.44 Billion | $105.13 Billion | +0.14pp |
| 2010-12-31 | 1.23% | $1.30 Billion | $105.78 Billion | +0.97pp |
| 2009-12-31 | 0.26% | $293.00 Million | $112.31 Billion | -2.11pp |
| 2008-12-31 | 2.37% | $1.12 Billion | $47.20 Billion | -3.62pp |
| 2007-12-31 | 5.99% | $2.89 Billion | $48.35 Billion | -0.29pp |
| 2006-12-31 | 6.28% | $2.80 Billion | $44.57 Billion | -7.22pp |
| 2005-12-31 | 13.50% | $6.05 Billion | $44.85 Billion | +3.60pp |
| 2004-12-31 | 9.89% | $4.21 Billion | $42.57 Billion | +2.57pp |
| 2003-12-31 | 7.32% | $2.97 Billion | $40.59 Billion | +1.59pp |
| 2002-12-31 | 5.74% | $2.73 Billion | $47.56 Billion | +3.14pp |
| 2001-12-31 | 2.60% | $1.14 Billion | $44.02 Billion | -1.71pp |
| 2000-12-31 | 4.30% | $1.72 Billion | $39.91 Billion | +0.99pp |
| 1999-12-31 | 3.31% | $1.18 Billion | $35.63 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more